Purpose: To evaluate the efficacy and safety of intrasilicone injection of bevacizumab for the treatment of iris neovascularization after vitrectomy for proliferative diabetic retinopathy. Methods: Bevacizumab 1.25 mg/0.05 ml was injected into silicone oil in 15 eyes of 11 patients with iris neovascularization which had developed 2.5–6 months after vitrectomy and silicone oil tamponade. The main outcome measures were regression of iris neovascularization, intraocular pressure elevation, and visual acuity. Results: In all eyes, iris neovascularization regressed and postinjection intraocular pressure was controlled within 7 days postinjection. Visual acuity improved in 12 eyes. In 4 patients, iris neovascularization recurred within 10 weeks after the injection and they were successfully treated with a second intrasilicone bevacizumab injection of the same dose. Conclusion: Intrasilicone injection of bevacizumab is safe and effective in the treatment of patients with iris neovascularization after vitrectomy for advanced proliferative diabetic retinopathy. Further studies on greater numbers of patients and more advanced neovascularization are recommended.

Keywords:
Diabetic retinopathy, Bevacizumab, Silicone oil, Vitrectomy, Iris neovascularization
1.
Avery RL: Regression of retinal and iris neovascularization after intravitreal bevacizumab (Avastin) treatment. Retina 2006;26:352–354.
2.
Sivak-Callcott JA, O’Day DM, Gass DM, Tsai JC: Evidence-based recommendations for the diagnosis and treatment of neovascular glaucoma. Ophthalmology 2001;108:1767–1776.
3.
Ferrara N: Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 2004;25:581–611.
4.
Ryan M, Philip J, Carmen A, et al: Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age related macular degeneration. Retina 2006;26:495–511.
5.
Rodrigo J, Rogrio A, Daniela C, et al: Intravitreal bevacizumab (Avastin) for persistent new vessels in diabetic retinopathy (IBEPE study). Retina 2006;26:1006–1013.
6.
Rosenfeld PJ: Intravitreal Avastin: the low cost alternative to Lucentis? Am J Ophthalmol 2006;142:141–143.
7.
Gallemore RP, McCuen BW: Silicone oil in vitreoretinal surgery; in Ryan SJ (ed): Retina, ed 4. St. Louis, Mosby, 2006, pp 2211–2234.
8.
Teich SA, Walsh JB: A grading system for iris neovascularization: prognostic implications for treatment. Ophthalmology 1981;88:1102–1106.
9.
Ehrenberg M, McCuen BW, Schindler RH, et al: Rubeosis iridis: preoperative iris fluorescein angiography and periocular steroids. Ophthalmology 1984;91:321–325.
10.
Oshima Y, Sakaguchi H, Gomi F, Tano Y: Regression of iris neovascularization after intravitreal injection of bevacizumab in patients with proliferative diabetic retinopathy. Am J Ophthalmol 2006;142:155–158.
11.
Wakabayashi T, Oshima Y, Sakaguchi H, Ikuno Y, Miki A, Gomi F, et al: Intravitreal bevacizumab to treat iris neovascularization and neovascular glaucoma secondary to ischemic retinal diseases in 41 consecutive cases. Ophthalmology 2008;115:1571–1580.
12.
Cheng JY, Wong DW, Ang CL: Intraocular Avastin (bevacizumab) for neovascularisation of the iris and neovascular glaucoma. Ann Acad Med Singapore 2008;37:72–74.
13.
Grisanti S, Biester S, Peters S, Tatar O, Ziemssen F, Bartz-Schmidt KU, Tuebingen Bevacizumab Study Group: Intracameral bevacizumab for iris rubeosis. Am J Ophthalmol 2006;142:158–160.
14.
Iliev ME, Domig D, Wolf-Schnurrbursch U, Wolf S, Sarra GM: Intravitreal bevacizumab (Avastin) in the treatment of neovascular glaucoma. Am J Ophthalmol 2006;142:1054–1056.
15.
Haritoglou C, Kook D, Neubauer A, Wolf A, Priglinger S, Strauss R, et al: Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema. Retina 2006;62:999–1005.
16.
Silva Paula J, Jorge R, Alves Costa R, Rodrigues Mde L, Scott IU: Short-term results of intravitreal bevacizumab (avastin) on anterior segment neovasculariztion in neovascular glaucoma. Acta Ophthalmol Scand 2006;84:556–557.
17.
Manzano RP, Peyman GA, Khan P, Kivilcim M: Testing intravitreal toxicity of bevacizumab (Avastin). Retina 2006;26:257–261.
© 2012 S. Karger AG, Basel
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.